Mauna Kea Technologies Announces Strategic Realignment
Company to focus resources on robotic assisted interventional pulmonology and molecular imaging
Nicolas Bouvier, member of the Executive Committee, appointed as Interim CEO
Mauna Kea Technologies announced a realignment of the organization designed to improve operating efficiency, increase the company’s cash runway, and focus resources on Cellvizio’s highest potential clinical applications, including interventional pulmonology and molecular imaging.
Effective immediately, Robert Gershon has resigned as Chief Executive Officer and has stepped down as a member of the Board of Directors. Nicolas Bouvier, a member of the Executive Committee since 2019, will serve as Interim Chief Executive Officer while the Board begins an external search for a permanent CEO. Before joining Mauna Kea, Mr. Bouvier spent 10 years at Novartis Oncology and Sandoz in a series of senior human capital management roles.
“The Board of Directors of Mauna Kea Technologies recognizes its responsibility to create value while being effective stewards of capital,” stated Sacha Loiseau, Ph.D., Founder and Chairman of the Board of Directors of Mauna Kea Technologies. “We thank Rob for his contributions during his 3-year tenure and wish him well.”
The strategic realignment announced today targets a more capital-efficient operating model, ensures the completion of previously announced clinical programs in endoluminal robotics and bronchoscopic systems, and supports gastroenterologists using Cellvizio to deliver patient care.
Molly O’Neil, board member and chair of the Audit and Compliance Committee added, “We are very fortunate to have a talented executive team with the experience and passion to lead Mauna Kea to its fullest potential. We look forward to supporting Nicolas in his interim role.”
Sacha Loiseau concluded, “With its broad regulatory clearances, unrivaled clinical evidence and unique imaging capabilities, Cellvizio has the capacity to enhance robotic and navigation platforms, deliver on the promise of molecular imaging, and support advanced therapeutic treatments. The Mauna Kea Board believes this realignment will enable Mauna Kea to better meet the needs of its clinicians, employees, and shareholders.”